STOCK TITAN

Dr Reddys Labs - RDY STOCK NEWS

Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.

Dr. Reddy's Laboratories (RDY) maintains its position as a global pharmaceutical innovator through strategic developments in generic medicines, biosimilars, and active pharmaceutical ingredients. This news hub provides investors and industry professionals with essential updates on corporate milestones, regulatory filings, and market expansions.

Access real-time information about earnings announcements, partnership agreements, and product pipeline advancements. Our curated collection features official press releases covering FDA approvals, manufacturing facility certifications, and therapeutic area breakthroughs in oncology and gastroenterology.

Monitor critical updates including patent litigation outcomes, emerging market entries, and sustainability initiatives. The repository serves as a reliable resource for understanding RDY's operational strategies and quality compliance across 75+ countries.

Bookmark this page for streamlined access to verified updates about Dr. Reddy's Laboratories. Check regularly for insights into biosimilar developments, API production innovations, and financial performance indicators shaping the global pharmaceutical landscape.

Rhea-AI Summary
Dr. Reddy's tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in a Phase I study. The study demonstrated pharmacokinetic equivalence, safety, and immunogenicity compared to reference products. Dr. Reddy's is now initiating a global Phase III study to compare efficacy, safety, tolerability, and immunogenicity with the reference product.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.55%
Tags
-
Rhea-AI Summary
Dr. Reddy’s Laboratories announced its financial results for Q4 and FY23. Q4 revenue was up 16% YoY and down 7% QoQ. Gross margin was 57.2%. EBITDA was 25.9% of revenues, up 26% YoY and down 17% QoQ. Profit before tax was up 434% YoY and down 19% QoQ. Profit after tax was up 996% YoY and down 23% QoQ.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
-
Rhea-AI Summary
Coya Therapeutics announces positive clinical data for COYA 302 in ALS patients and upcoming presentation on COYA 301 in Alzheimer's Disease. The company also appoints new Chief Business Officer and enters into licensing agreements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
Rhea-AI Summary
Dr. Reddy's Laboratories launches generic version of Regadenoson Injection in the U.S. market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none
-
Rhea-AI Summary

Dr. Reddy's Laboratories Ltd. (NYSE: RDY) has launched Treprostinil Injection in the U.S., marking its introduction as a therapeutic equivalent generic version of Remodulin® (treprostinil) Injection, which has been approved by the U.S. Food and Drug Administration.

The drug is available in multiple vial strengths: 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, and 200 mg/20 mL. This strategic launch is positioned to enhance the company's portfolio in the cardiovascular treatment domain, reinforcing its commitment to providing affordable medicines.

For detailed prescribing information and additional insights into Dr. Reddy's offerings, please visit the company’s official website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.31%
Tags
none
-
Rhea-AI Summary

Aditxt, Inc. (NASDAQ: ADTX) has signed an asset purchase agreement with Cellvera, granting Aditxt a 50% stake in Global Response Aid (GRA), a partnership with Agility. The deal involves a total transaction value of $24.5 million, which includes the forgiveness of a $14.5 million loan and $10 million in cash, alongside future royalties over seven years. This strategic acquisition aims to expand Aditxt’s capabilities in developing effective antiviral therapies, particularly focusing on the drug Avigan, which is licensed for use in multiple markets excluding Japan, China, and Russia. The agreement is contingent upon various approvals, including board and regulatory consents. Aditxt's CEO emphasizes that this acquisition is pivotal for driving future growth and addressing the rising demand for antiviral solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
Rhea-AI Summary

Coya Therapeutics (Nasdaq: COYA) reported its fiscal year 2022 results, highlighting key developments in its drug pipeline. The company achieved positive results in a clinical study of COYA 302 for ALS, showing halted disease progression over 6 months. Coya also entered into a worldwide agreement with Dr. Reddy's Laboratories (NYSE: RDY) to out-license its COYA 301 product candidate.

The company raised approximately $16.4 million from its IPO in January 2023, with cash and equivalents of $5.9 million as of December 31, 2022. However, Coya reported a net loss of $12.2 million for 2022, attributed to increased R&D and administrative expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
-
Rhea-AI Summary

Coya Therapeutics, Inc. (NASDAQ: COYA) has entered into a worldwide agreement with Dr. Reddy’s Laboratories (NYSE: RDY) to develop COYA 302, an investigational combination biologic for neurodegenerative diseases. This product consists of COYA 301 and CTLA4-Ig (Abatacept), targeting chronic inflammation. Coya retains exclusive rights for commercialization in North America, Europe, and Japan, while Dr. Reddy’s can commercialize outside these territories. Coya plans to file an IND in the second half of 2023, aiming for a phase 1b/2 trial in Amyotrophic Lateral Sclerosis (ALS) shortly thereafter. The partnership is expected to enhance Coya’s development efforts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
none
-
Rhea-AI Summary

Dr. Reddy's Laboratories SA, a wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., has signed a definitive agreement to acquire the U.S. generic prescription product portfolio from Mayne Pharma Group Limited for approximately $90 million in cash. The portfolio includes 45 commercial products, 4 pipeline products, and 40 approved non-marketed products, with a total revenue of $111 million reported for the last financial year. This acquisition aims to enhance Dr. Reddy’s presence in the women’s health market and accelerate access to affordable medications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
Dr Reddys Labs

NYSE:RDY

RDY Rankings

RDY Stock Data

2.33B
833.15M
15.04%
2.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
India
Hyderabad